Biotech Values

[ciotera]

PI-based regimens are all but obsolete..

That is a premature conclusion, I think. Boosted PIs will hold their ground. They are still the preferred regimen for patients with very high VL and whenever one needs a longer half-life/higher barrier to resistance (unlike Isentress and Atripla which are now obsolete).